New and emerging treatments for osteoporosis

Current Opinion in Rheumatology

Volumn 19, Issue 4, 2007, Pages 364-369

  Maricic, Michael ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Catalina Pointe Clinical Research Inc   (United States)

Author keywords

Denosumab; Ibandronate; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; GERANYLTRANSFERASE; GLUCOCORTICOID; IBANDRONIC ACID; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; VITAMIN D; ZOLEDRONIC ACID;

ADRENAL INSUFFICIENCY; BONE NECROSIS; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMUR NECK; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; HYPOCALCEMIA; IMMUNE DYSREGULATION; JAW DISEASE; KIDNEY DYSFUNCTION; MALABSORPTION; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE;

EID: 34250003076     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328172dc1a     Document Type: Review

References (26)

1. Osterberg L, Blaschke T. Adherence to medications. N Engl J Med 2005; 353:487-497.
2. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14:965-968.
3. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003-1008.
4. Siris ES, Harris ST, Rosen CR. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013-1022.
5. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 2005; 37:433-440.
6. Weycker D, Macarios D, Edelsberg J. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17:1645-1652.
7. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
8. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20:1315-1322.
9. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006; 54:1838-1846.
10. Green JR, Rogers MJ. Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002; 55:210-224.
11. Nancollas G, Tang R, Guide S, et al. Mineral binding affinities and zeta potentials of bisphosphonates. J Bone Miner Res 2002; 17:S368.
12. Viereck V, Emons G, Lauck V, et al. The bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002; 291:680-686.
13. Reid IR, Brown JP, Burckhardt PB, et al. Intravenous zoledronic acid in posmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653-661.
14. Black DMB, Cauley J, Delmas P, et al. Effect of once-yearly infusion of zoledronic acid 5mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial. J Bone Miner Res 2006; 21:S16.
15. Markowitz GS, Fine PL, Stack JL, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64:281-289.
16. Holick MF, Siris ES, Binkley N. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90:3215-3224.
17. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
18. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005; 208:30-49.
19. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
20. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-323.
21. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
22. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
23. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausalwomen. J Bone Miner Res 2001; 16:348-360.
24. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059-1066.
25. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-831. This is the first study to show that denosumab reduced bone turnover and increased BMD in postmenopausal women with low BMD.
26. Lewiecki EM, Miller PD, McClung MR, et al. RANK ligand inhibition with denosumab (AMG 162) increases bone mineral density in postmenopausal women after two years of treatment [abstract]. Arthritis Rheum 2005; 52:4108.